PLAUR抗体PLAUR兔多抗抗体urokinase-typ
e plasminogen activator (uPA) receptor antibody抗体PLAUR Antibody抗体- ￥440 - 1320
- CUSABIO
- CN
- CSB-PA07505A0Rb
- 2025年07月12日
- ELISA, WB, IHC, IF; Recommended dilution: WB:1:1000-1:5000, IHC:1:200-1:500, IF:1:50-1:200
- Rabbit
- Human, Mouse
企业认证
相关产品推荐更多 >
ZNF529抗体ZNF529兔多抗抗体ZNF529 antibody抗体ZNF529 Antibody, FITC conjugated抗体
￥880
XPO6抗体XPO6一抗抗体XPO6_HUMAN antibody抗体XPO6 Antibody抗体
￥3900Lgals4抗体Lgals4兔多抗抗体Lactose-binding lectin 4 antibody抗体Lgals4 Antibody, FITC conjugated抗体
￥880
SORBS3抗体SORBS3兔多抗抗体Sorbin and SH3 domain-containing protein 3 antibody抗体SORBS3 Antibody, Biotin conjugated抗体
￥880TMCO1抗体TMCO1兔多抗抗体Xenogeneic cross-immune protein PCIA3抗体TMCO1 Antibody, Biotin conjugated抗体
￥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human Urokinase plasminogen activator surface receptor protein (23-305AA)
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
Polyclonal
- 标记物：
Non-conjugated
- 适应物种：
Human, Mouse
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
Q03405
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA, WB, IHC, IF; Recommended dilution: WB:1:1000-1:5000, IHC:1:200-1:500, IF:1:50-1:200
- 浓度：
>95%,Protein G purified
- 靶点：
PLAUR
- 抗体英文名：
PLAUR Antibody
- 抗体名：
urokinase-type plasminogen activator (uPA) receptor antibody
- 规格：
100μg/50μg/20μg
| 规格： | 100μg | 产品价格： | ￥1320.0 |
|---|---|---|---|
| 规格： | 50μg | 产品价格： | ￥880.0 |
| 规格： | 20μg | 产品价格： | ￥440.0 |
保存缓冲液
Preservative: 0.03% Proclin 300Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
功能
Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验is almost catalytic when compared to antisense silencing. Of these targets, the uPAR-uPA system and MMPs holds great promise. Targeting uPA/uPAR may provide additive or synergistic treatment benefits if used in combination with conventional therapeutics
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene
attachments. One such enzyme, the serine protease urokinase-type plasminogen activator (uPA), converts enzymatically inactive plasminogen into the widely acting protease plasmin, which degrades several extracellular matrix components and also activates
of pericellular proteases; among those, the serine protease, urokinase-type plasminogen activator (uPA), its inhibitor PAI-1, and its cellular receptor uPA-R (CD87). Apart from its proteolytic functions, the uPA system is endowed with properties affecting
技术资料暂无技术资料 索取技术资料
